Mayo Clinic Arizona’s Urologic Oncology Fellowship has received 5-year SUO accreditation for one fellow per year. Grateful to our faculty, education team, leadership, and SUO fellowship committee and executive board. Excited to train the next generation! @MayoUrology
🚨 MRI-first screening w/o contrast finds more ≥GG2 #ProstateCancer 🚨
@EurUrol
👥 759 pts randomized
📊 Biparametric MRI first vs MRI only if PSA ≥3
⏱️ 15 min scan, no contrast
✅ csPCa detected: 4.6% vs 1.8% (RR 2.6, 95% CI 1.1-6.1)
✅ Several csPCa found in pts w/ normal PSA
⚠️ More biopsies in MRI-first arm (10.8% vs 5.2%)
🎯 A FAST⚡️ contrast-free MRI up front catches significant PCa a PSA screen might miss
@PCF_Science@PCFnews@urotoday@UrologyTimes@UroOnc
🔗https://t.co/E8rXTQL1nW
@RamPathakMD We are very excited and honored to have you join us in Sedona! We can’t wait to delve into how to balance traditional treatment choices with novel alternatives. Will be great to have you and @JackAndrewsMD provide your insights on cutting edge prostate cancer Rx.
Great conversation with @RepDavid and @JasonJamesonMD about AI in healthcare, improving efficiency and reducing administrative burden/waste. Thank you @AmerUrological for a fantastic Advocacy Summit #AUASummit25
POSTER 2) Among men undergoing MR fusion prostate biopsy for unilateral PIRADS 3 or
4 lesions, transperineal biopsy resulted in greater disease detection for both targeted fusion and systematic samples. TP biopsy may provide a more thorough pre-treatment assessment for FT.
@MayoUrology with two posters at #FOCAL2024 POSTER 1) Those are active surveillance with PIRADS 5 lesions disease have lower rates of high-grade disease on targeted biopsy, compared to those with no previous prostate cancer diagnosis. @dfrendl
@LondonProstate1 And we of course know and practice surgery and radiation as the cornerstone of treating clinically significant prostate cancer. The course was very fair and balanced and emphasized avoiding over diagnosis and over treatment.
@LondonProstate1 Irony is that radiation is the most common modality used to over treat prostate cancer… For those interested in criticizing these courses they should join us to listen to what we discuss and help advance the science rather than make political commentary
@FrancisMedical@MayoClinic@LanceMynderse We are excited to offer our patients with Gleason 3+4 prostate cancer and MRI visible localized prostate cancer the option to participate in the VAPOR2 clinical trial for focal therapy!
Another win for focal therapy
Prostate cancer focal therapy (using HIFU & cryotherapy) is cost effective compared to radical therapy
Lower cost, better quality of life https://t.co/TR7CQuCUeh
Proud of my wife Anna Ward and the outstanding group of women leaders @MGHanesthesia for their work supporting our colleagues who are amazing mothers!
Championing the Mom: The Role of a Mother’s Support Group... : Anesthesia & Analgesia https://t.co/3XWMlyDtLJ